Physician profile
Manh Dang
NPI 1780663880
$4,070.65
in general payments reported to CMS, 2019-2025
52 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $669 · 2021: $920 · 2022: $443 · 2023: $201 · 2024: $297 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606 · Education: $49.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.40 |
| Education | $49.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $432.31 | 2021 | |
| Merck Sharp & Dohme LLC | $345.74 | 2019-2024 | Welireg, Keytruda |
| Pfizer INC. | $295.58 | 2019-2025 | |
| Amgen INC. | $270.82 | 2019-2022 | |
| Janssen Biotech, INC. | $245.55 | 2019-2025 | Talvey, Tecvayli, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $221.59 | 2019-2021 | |
| Astellas Pharma US INC | $220.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $180.80 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $175.79 | 2020-2025 | Enhertu, Lynparza |
| Incyte Corporation | $125.56 | 2019-2024 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $102.98 | 2019-2023 | Imbruvica |
| Seagen INC. | $93.95 | 2020 | |
| Daiichi Sankyo INC. | $75.01 | 2021-2025 | Enhertu |
| Genzyme Corporation | $74.66 | 2019-2021 | |
| Genentech USA, INC. | $74.53 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manh Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.